Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: A randomized controlled trial

Obstetrics and Gynecology

Volumn 109, Issue 3, 2007, Pages 588-596

  Simon, James A ^a   Bouchard, Celine ^a   Waldbaum, Arthur ^a   Utian, Wulf ^a   Zborowski, Joanne ^a   Snabes, Michael C ^a  

^a C/o BioSante Pharmaceuticals Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ELESTRIN; ESTRADIOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; BREAST DISEASE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY SKIN; ENDOMETRIUM HYPERPLASIA; ERYTHEMA; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERPLASIA; LOW DRUG DOSE; MASTALGIA; MATURATION; MENOPAUSAL SYNDROME; METRORRHAGIA; MIGRAINE; MULTICENTER STUDY; NAUSEA; OVARY TUMOR; PARALLEL DESIGN; PERIPHERAL EDEMA; PH; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REPRODUCTIVE TOXICITY; RESTLESS LEGS SYNDROME; SIDE EFFECT; SWELLING; VAGINA ATROPHY; VAGINA DISCHARGE; VASOMOTOR DISORDER;

ADMINISTRATION, CUTANEOUS; ATROPHY; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; GELS; HUMANS; MIDDLE AGED; POSTMENOPAUSE; VAGINA; VASOMOTOR SYSTEM; VULVA;

EID: 33847405256     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000254160.62588.41     Document Type: Article

References (27)

1. Sikon A, Thacker HL. Treatment options for menopausal hot flashes. Cleve Clin J Med 2004;71:578-82.
2. Treatment of menopausal vasomotor symptoms. Med Lett Drugs Ther 2004;46:97-102.
3. U.S. Department of Health and Human Services. Menopause and menopause treatments. womenshealth.gov. Available at: http://www.womanshealth.gov/faq/ menopaus.htm. Retrieved December 1, 2006.
4. Endocrinologists' guidelines for the diagnosis and treatment of menopause. Medscape. Available at: http://www.medscape.com/viewarticle/ 540531_11. Retrieved December 1, 2006.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
6. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
7. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-58.
8. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
9. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006;166:357-65.
10. Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004;24:217-21.
11. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118:74S-8S.
12. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118 suppl:163-5.
13. Center for Drug Evaluation and Research. Guidance for industry: noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommended prescribing information for health care providers and patient labeling. Nov Labeling Revision 4 (draft). Rockville (MD): US Department of Health and Human Services, Food and Drug Administration; 2005.
14. McKenzie J, Jaap AJ, Gallacher S, Kelly A, Crawford L, Greer IA, et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol (Oxf) 2003;59:682-9.
15. Center for Drug Evaluation and Research . Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. Jan (draft). Rockville (MD): US Department of Health and Human Services, Food and Drug Administration; 2003.
16. Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002;9:402-10.
17. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-75.
18. Vasomotor symptoms. Obstet Gynecol 2004;104:106S- 117S.
19. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11-33.
20. U.S. Food and Drug Administration. Menopause and hormones. Available at: http://www.fda.gov/womens/menopause/mht-FS.html. Retrieved December 1, 2006.
21. den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507-12.
22. Continuation rates for oral contraceptives and hormone replacement therapy. The ESHRE Capri Workshop Group. Hum Reprod 2000;15:1865-71.
23. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779-87.
24. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff . Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-8.
25. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;291:1610-20.
26. Hulley SB, Grady D. The WHI estrogen-alone trial - do things look any better? JAMA 2004;291:1769-71.
27. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study [published erratum appears in Lancet. 2003;362:1160]. Lancet 2003;362:419-27.